Loxo drug shows activity in leukemia, lymphoma patients resistant to marketed therapies at ASH
Data showed LOXO-305 was broadly effective in patients resistant to BTK inhibitors regardless of whether they harbored a putative mechanism of resistance to the widely used blood cancer drugs.